What's new AAPOS 2008 - The Private Eye Clinic

Treatment of retinoblastoma: Current status and future perspectives.
Rodriguez-Galindo C, Chantada GL, Haik BG, Wilson MW.
Curr Treat Options Neurol 2007 Jul; 9(4):294-307.
This is a good review article delineating the current treatment status for RB. They
emphasize that the treatment must always be individualized. They review the various
treatment modalities: surgery, focal therapy (photocoagulation, cryo, and
thermotherapy), radiation therapy and chemotherapy. Each of the specific chemo
agents is reviewed. They touch on the emerging therapies and provide an opinion
statement.
Eye size in retinoblastoma: MR imaging measurements in normal and affected
eyes.
De Graaf P, Knol DL, Moll AC, Imhof SM et al.
Radiology 2007 Jul; 244(1):273-80
This is a retrospective study of 100 eyes (50 boys/50girls) with RB over a 12 year
period. They used MR imaging to measure axial length (AL), equatorial diameter ED)
and eye volume (EV). Normal eyes of patients with unilateral retinoblastoma served as
controls. Eyes with Rb had significantly shorter AL’s and EDs and significantly smaller
EVs than normal eyes. In those eyes with Rb, the larger the tumor volume, the smaller
the eye.
One hit, two hits, three hits, more? Genomic changes in the development of
retinoblastoma.
Corson TW, Gallie BL.
Genes Chromosomes Cancer 2007 Jul; 46(7):617-34.
RB is initiated by the loss of both alleles of the prototypic tumor suppressor gene RB1.
However a large number of cytogenetic and comparative genomic hybridization studies
have shown that the M1 and M2 mutational events are not the only genomic changes in
RB. The authors review these subsequent changes which are likely crucial for tumor
progression. The authors provide a comprehensive summary of the genomic evidence
implicating gain of 1q, 2p, 6p, and 13q and loss of 16q in RB oncogenesis. They
discuss the search for candidate oncogenes and tumor suppressor genes within these
regions and their potential diagnostic, prognostic, and therapeutic implications.
Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma.
Zage PE, Reitman AJ, Seshadri R, et al
Pediatr Blood Cancer, 2007 Aug 29 [Epub ahead of print]
69